Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function. RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons). CONCLUSIONS: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TZDs have a high durability of glycemic response, most likely through a potent effect on preserving b -cell function (196).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study examined the impact of lifestyle and medications in a young cohort with diabetes duration of less than a year and found glycaemia to be best managed by the combination of rosiglitazone and metformin, with the addition of lifestyle to metformin being no better than metformin alone161.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [161]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationUse and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Research works printed but not linked: 3
- 10.1210/jc.82.7.2108 · doi:10.1210/jc.82.7.2108 · Paper page
- Harris SB, 2004, Can Fam Physician, 50, 425
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
Cited by
Items 701–800 of 1,014
Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors
Hollander, P. A., & Kushner, P. R. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2144 · Cited by 60
Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus
STOLAR, M. W. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0471 · Cited by 66
Diabetes in Mice With Selective Impairment of Insulin Action in Glut4-Expressing Tissues
Lin, H. V., Ren, H., Samuel, V. T., Lee, H.-Y., Lu, T. Y., Shulman, G. I., & Accili, D. (2011) · Diabetes · doi:10.2337/db10-1056 · Cited by 59
Lundqvist, A., Steen Carlsson, K., Johansen, P., Andersson, E., & Willis, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110235 · Cited by 59
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
Standl, E., Schnell, O., & McGuire, D. K. (2016) · Circulation Research · doi:10.1161/circresaha.116.306924 · Cited by 59
Tabaei, B. P., Rundle, A., Wu, W. Y., Horowitz, C. R., Mayer, V., Sheehan, D. M., & Chamany, S. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx300 · Cited by 60
García-Calzón, S., Perfilyev, A., Martinell, M., Ustinova, M., Kalamajski, S., Franks, P. W., Bacos, K., Elbere, I., Pihlajamäki, J., Volkov, P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz1803 · Cited by 65
TZDs and Bone: A Review of the Recent Clinical Evidence
Schwartz, A. V. (2008) · PPAR Research · doi:10.1155/2008/297893 · Cited by 63
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes
Deacon, C. F. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.4.533 · Cited by 59
Complications of Diabetes Therapy
Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 65
Osman, I., & Segar, L. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.11.026 · Cited by 63
Kibirige, D., Sekitoleko, I., Lumu, W., Jones, A. G., Hattersley, A. T., Smeeth, L. L., & Nyirenda, M. (2022) · Diabetologia · doi:10.1007/s00125-021-05644-8 · Cited by 61
The Economics of Diabetes Prevention
Herman, W. H. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.11.010 · Cited by 60
Self-citationPreiss, D., Sattar, N. A., & McMurray, J. J. V. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.10.019 · Cited by 63
Rosiglitazone Decreases Bone Mass and Bone Marrow Fat
Harsløf, T., Wamberg, L., Møller, L., Stødkilde-Jørgensen, H., Ringgaard, S., Pedersen, S. B., & Langdahl, B. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2077 · Cited by 57
Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis
Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.08.024 · Cited by 65
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised)
(2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872287 · Cited by 69
McCarthy, A. D., Cortizo, A. M., & Sedlinsky, C. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i6.122 · Cited by 63
Basterra-Gortari, F. J., Ruiz-Canela, M., Martínez-González, M. A., Babio, N., Sorlí, J. V., Fito, M., Ros, E., Gómez-Gracia, E., Fiol, M., Lapetra, J., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2475 · Cited by 59
Composite and surrogate outcomes in randomised controlled trials
Freemantle, N., & Calvert, M. (2007) · BMJ · doi:10.1136/bmj.39176.461227.80 · Cited by 60
Molecular mechanisms of action of metformin: latest advances and therapeutic implications
Zhu, H., Jia, Z., Li, Y. R., & Danelisen, I. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01051-y · Cited by 61
Regulation of glucose metabolism and the skeleton
Ng, K. W. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04133.x · Cited by 63
Barnett, A., Allsworth, J., Jameson, K., & Mann, R. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x199691 · Cited by 57
Cardiovascular risk and thiazolidinediones—what do meta‐analyses really tell us?
Schernthaner, G., & Chilton, R. J. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01262.x · Cited by 58
The response to short‐term intensive insulin therapy in type 2 diabetes
Retnakaran, R. R., Yakubovich, N., Qi, Y., Opsteen, C., & Zinman, B. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01129.x · Cited by 58
Self-citationColagiuri, S., Matthews, D. R., Leiter, L. A., Chan, S. P., Sesti, G., & Marre, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.028 · Cited by 63
Novel approaches to restore beta cell function in prediabetes and type 2 diabetes
Salunkhe, V. A., Veluthakal, R., Kahn, S. E., & Thurmond, D. C. (2018) · Diabetologia · doi:10.1007/s00125-018-4658-3 · Cited by 65
Self-citationThiazolidinediones induce osteocyte apoptosis and increase sclerostin expression
Mabilleau, G., Mieczkowska, A., & Edmonds, M. E. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03048.x · Cited by 58
Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56
“Three trials provided nonspecific data on HF episodes during follow-up without detailing associated death, hospitalization, or need for escalated HF treatment (25,38,39).”
BackgroundThe Look AHEAD Trial: Bone Loss at 4-Year Follow-up in Type 2 Diabetes
Lipkin, E. W., Schwartz, A. V., Anderson, A. M., Davis, C., Johnson, K. C., Gregg, E. W., Bray, G. A., Berkowitz, R., Peters, A. L., Hodges, A., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0762 · Cited by 57
Self-citationVinik, A. I. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.005 · Cited by 61
Wheeler, S., Moore, K. P., Forsberg, C. W., Riley, K., Floyd, J. S., Smith, N. L., & Boyko, E. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2958-1 · Cited by 57
Reaven, G. M. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109336038 · Cited by 60
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
Chon, S., & Gautier, J. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.2.99 · Cited by 66
Ion Channels of the Islets in Type 2 Diabetes
Jacobson, D. A., & Shyng, S. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.08.014 · Cited by 65
Juurinen, L., Kotronen, A., Granér, M., & Yki‐Järvinen, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1825 · Cited by 58
Optimizing Cardiovascular Outcomes in Diabetes Mellitus
Sobel, B. E. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.07.002 · Cited by 60
(How) Can We Prevent Type 2 Diabetes?
Buchanan, T. A. (2007) · Diabetes · doi:10.2337/db07-0140 · Cited by 55
History of Discovery: Platelet-Derived Growth Factor
Bowen‐Pope, D. F., & Raines, E. W. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179556 · Cited by 69
D'Alessio, D., Häring, H. ‐., Charbonnel, B., de Pablos‐Velasco, P., Candelas, C., Dain, M. ‐., Vincent, M., Pilorget, V., Yki‐Järvinen, H., & on behalf of the EAGLE Investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12406 · Cited by 56
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55
Tolman, K. G., Freston, J. W., Kupfer, S., & Pérez, A. (2009) · Drug Safety · doi:10.2165/11316510-000000000-00000 · Cited by 61
In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
He, B. K., Ning, Z. Q., Li, Z. B., Shan, S., Pan, D. S., Ko, B. C. B., Li, P. P., Shen, Z. F., Dou, G. F., Zhang, B. L., et al. (2012) · PPAR Research · doi:10.1155/2012/546548 · Cited by 53
Shimo, N., Matsuoka, T., Miyatsuka, T., Takebe, S., Tochino, Y., Takahara, M., Kaneto, H., & Shimomura, I. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.038 · Cited by 55
Telephone Intervention to Improve Diabetes Control
Chamany, S., Walker, E. A., Schechter, C. B., Gonzalez, J. S., Davis, N. J., Ortega, F. M., Carrasco, J., Basch, C. E., & Silver, L. D. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.04.016 · Cited by 55
IAPP/amylin and β-cell failure: implication of the risk factors of type 2 diabetes
Kanatsuka, A., Kou, S., & Makino, H. (2018) · Diabetology International · doi:10.1007/s13340-018-0347-1 · Cited by 63
Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis
Long, Y., Liu, M., Huang, Y., Wu, K., Huang, X., Zhao, Y., He, W., & Zhang, R. (2019) · Disease Markers · doi:10.1155/2019/6230162 · Cited by 61
Evaluation and Treatment of Prediabetes in Youth
Magge, S. N., Silverstein, J. H., Elder, D. A., Nadeau, K. J., & Hannon, T. S. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.12.061 · Cited by 62
PPAR Ligands: Are They Potential Agents for Cardiovascular Disorders?
Balakumar, P., Rose, M., & Singh, M. (2007) · Pharmacology · doi:10.1159/000102594 · Cited by 60
Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes
DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators (2011) · Diabetologia · doi:10.1007/s00125-010-1985-4 · Cited by 54
“These DREAM On findings indicate that 3 years of treatment have a legacy effect on incident diabetes, and a recent study in newly diagnosed people with diabetes, in which rosiglitazone therapy achieved durable glycaemic control compared with either metformin or glybenclamide [17], suggests that rosiglitazone preserves…”
BackgroundThe Functions of PPARs in Aging and Longevity
Erol, A. (2007) · PPAR Research · doi:10.1155/2007/39654 · Cited by 54
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
Rosenstock, J., Niggli, M., & Maldonado‐Lutomirsky, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01021.x · Cited by 57
The role of glimepiride in the treatment of type 2 diabetes mellitus
Briscoe, V. J., Griffith, M. L., & Davis, S. N. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903512955 · Cited by 65
Precision Medicine in Diabetes: Is It Time?
Florez, J. C. (2016) · Diabetes Care · doi:10.2337/dc16-0586 · Cited by 57
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino, F., Home, P. D., & Tuomilehto, J. (2016) · Diabetes Care · doi:10.2337/dcs15-3023 · Cited by 54
Lee, G., Oh, S.-W., Hwang, S.-S., Yoon, J. W., Kang, S., Joh, H.-K., Kwon, H., Kim, J., & Park, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177646 · Cited by 53
Diabetes and fragility fractures — A burgeoning epidemic?
Epstein, S., & LeRoith, D. (2008) · Bone · doi:10.1016/j.bone.2008.03.017 · Cited by 54
Benefits of timely basal insulin control in patients with type 2 diabetes
Lovre, D., & Fonseca, V. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.11.018 · Cited by 60
Acton, J. J., Akiyama, T. E., Chang, C. H., Colwell, L. F., Debenham, S. D., Doebber, T. W., Einstein, M., Liu, K., McCann, M. E., Moller, D. E., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900097m · Cited by 55
Regulation of Pancreatic Juxtaductal Endocrine Cell Formation by FoxO1
Kitamura, T., Kitamura, Y., Kobayashi, M., Kikuchi, O., Sasaki, T., DePinho, R. A., & Accili, D. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01622-08 · Cited by 53
PROactive: time for a critical appraisal
Betteridge, D. J., DeFronzo, R. A., & CHILTON, R. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn114 · Cited by 57
Okayasu, S., Kitaichi, K., Hori, A., Suwa, T., Horikawa, Y., Yamamoto, M., Takeda, J., & Itoh, Y. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.35.933 · Cited by 53
Thiazolidinediones: A 2010 Perspective
Krishnaswami, A., Ravi-Kumar, S., & Lewis, J. M. (2010) · The Permanente Journal · doi:10.7812/tpp/09-052 · Cited by 53
DeFronzo, R. A., CHILTON, R. J., Norton, L., Clarke, G., Ryder, R. E. J., & Abdul‐Ghani, M. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12652 · Cited by 55
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2017.12.003 · Cited by 70
PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells
Cheng, S., Qian, K., Wang, Y., Wang, G., Liu, X., Xiao, Y., & Wang, X. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14280 · Cited by 57
Ran, Q., Wang, J., Wang, L., Zeng, H., Yang, X., & Huang, Q. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00805 · Cited by 54
Fat and bone: the multiperspective analysis of a close relationship
Gómez, M. P. A., Benavent, C. A., Simoni, P., Aparisi, F., Guglielmi, G., & Bazzocchi, A. (2020) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims.2020.01.11 · Cited by 57
Metformin Should Not Be Used to Treat Prediabetes
Davidson, M. B. (2020) · Diabetes Care · doi:10.2337/dc19-2221 · Cited by 53
An update on preventive and regenerative therapies in diabetes mellitus
Reimann, M., Bonifacio, E. E., Solimena, M., Schwarz, P. E. H., Ludwig, B., Hanefeld, M., & Bornstein, S. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.11.009 · Cited by 64
Redefining the role of thiazolidinediones in the management of type 2 diabetes
Barnett (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4664 · Cited by 56
Early Insulin Treatment in Type 2 Diabetes
Meneghini, L. (2009) · Diabetes Care · doi:10.2337/dc09-s320 · Cited by 65
Lamontagne, J., Pepin, E., Peyot, M.-L., Joly, E., Ruderman, N. B., Poitout, V., Madiraju, S. R. M., Nolan, C. J., & Prentki, M. (2009) · Endocrinology · doi:10.1210/en.2008-1557 · Cited by 55
Five-Year Efficacy and Safety Data of Exenatide Once Weekly
Wysham, C., MacConell, L., Maggs, D. G., Zhou, M., Griffin, P. S., & TRAUTMANN, M. E. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.01.008 · Cited by 59
Dementia in Diabetes: The Role of Hypoglycemia
Husain, K. H., Sarhan, S. F., AlKhalifa, H. K. A. A., Buhasan, A., Moin, A. S. M., & Butler, A. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129846 · Cited by 58
Surrogate markers in clinical trials—Challenges and opportunities
Duivenvoorden, R., de Groot, E., Stroes, E. S. G., & Kastelein, J. J. P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.009 · Cited by 62
Staines, K. A., Zhu, D., Farquharson, C., & MacRae, V. E. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0493-2 · Cited by 56
Drug-induced hypoglycaemia in type 2 diabetes
Inkster, B., Zammitt, N. N., & Frier, B. M. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.694424 · Cited by 56
Alternate therapy of Type 2 diabetes mellitus (T2DM) with Nigella (Ranunculaceae)
Akash, M. S. H. (2011) · Journal of Medicinal Plants Research · doi:10.5897/jmpr11.1425 · Cited by 52
Beneficial Effect of Betulinic Acid on Hyperglycemia via Suppression of Hepatic Glucose Production
Kim, S. J., Quan, H. Y., Jeong, K. J., Kim, D. Y., Kim, G. W., Jo, H. K., & Chung, S. H. (2013) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf4030739 · Cited by 56
Tinahones, F. J., Gallwitz, B., Nordaby, M., Götz, S., Maldonado‐Lutomirsky, M., Woerle, H. J., & Broedl, U. C. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12814 · Cited by 53
New insights into antidiabetic drugs: Possible applications in cancer treatment
Shafiei‐Irannejad, V., Samadi, N., Salehi, R., Yousefi, B., & Zarghami, N. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13013 · Cited by 54
Sheu, W. H., Chan, S. P., Matawaran, B. J., Deerochanawong, C., Mithal, A., Chan, J. C. N., Suastika, K., Khoo, C. M., Nguyen, H. M., Ji, L., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0208 · Cited by 57
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
Lund, S. S., Tarnow, L., Astrup, A. S., Hovind, P., Jacobsen, P. K., Alibegovic, A. C., Parving, I., Pietraszek, L., Frandsen, M., Rossing, P., et al. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01079.x · Cited by 53
Patient-important outcomes in diabetes—time for consensus
Montori, V. M., Gandhi, G. Y., & Guyatt, G. H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61489-5 · Cited by 54
Lykkegaard, K., Larsen, P. J., Vrang, N., Bock, C., Bock, T. G., & Knudsen, L. B. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.05.011 · Cited by 57
Pérez, A., Zhao, Z., Jacks, R., & Spanheimer, R. G. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903350011 · Cited by 52
Nomura, S., Yamamoto, Y., Matsumura, Y., Ohba, K., Sakamaki, S., Kimata, H., Nakayama, K., Kuriyama, C., Matsushita, Y., Ueta, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400339b · Cited by 52
Fiorentino, T. V., Casiraghi, F., Davalli, A. M., Finzi, G., La Rosa, S., Higgins, P. B., Abrahamian, G. A., Marando, A., Sessa, F., Perego, C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.93091 · Cited by 51
Esposito, K., Ciotola, M., Maiorino, M. I., Gualdiero, R., Schisano, B., Ceriello, A., Beneduce, F., Feola, G., & Giugliano, D. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-8-200810210-00005 · Cited by 51
Lewin, A. J., Arvay, L., Liu, D., Patel, S. D., von Eynatten, M., & Woerle, H. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.07.008 · Cited by 54
Abbasi, F., Okeke, Q., & Reaven, G. M. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0461-2 · Cited by 57
Brunelli, S. M., Thadhani, R., Ikizler, T. A., & Feldman, H. I. (2009) · Kidney International · doi:10.1038/ki.2009.4 · Cited by 52
Charbonnel, B. H., DeFronzo, R. A., Davidson, J. A., Schmitz, O., Birkeland, K. I., Pīrāgs, V., Scheen, A. J., & on behalf of the PROactive investigators (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1974 · Cited by 54
Habib, Z. A., Tzogias, L., Havstad, S. L., Wells, K. E., Divine, G., Lanfear, D. E., Tang, J. M., Krajenta, R. J., Pladevall, M., & Williams, L. K. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1722 · Cited by 53
Lenin, R. R., Sankaramoorthy, A., Mohan, V., & Balasubramanyam, M. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a1214-609r · Cited by 54
Gunton, J. E., Cheung, N. W., Davis, T. M. E., Zoungas, S., & Colagiuri, S. (2014) · Medical Journal of Australia · doi:10.5694/mja14.01187 · Cited by 51
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 54
2020 vision – An overview of prospects for diabetes management and prevention in the next decade
Wang, C., Neil, D. L., & Home, P. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.007 · Cited by 57
Metadata
- Authors
- Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., & Viberti, G.
- Affiliations
- University of Washington (US)
- The University of Texas at San Antonio Health Science Center (US)
- GlaxoSmithKline (United States) (US)
- University of Michigan (US)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- George Washington University (US)
- Mount Sinai Hospital (CA)
- University of London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-12-07
- Volume
- 355
- Issue
- 23
- Pages
- 2427-2443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081276121
- Cited by
- 2,962
- References
- 37
- Citations by year
- 2026: 48 · 2025: 64 · 2024: 77 · 2023: 66 · 2022: 88 · 2021: 98 · 2020: 120 · 2019: 102 · 2018: 120 · 2017: 139 · 2016: 163 · 2015: 158 · 2014: 181 · 2013: 202 · 2012: 180
- FWCI
- 163.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, rosiglitazone, metformin, glibenclamide, thiazolidinediones, glycemic control, fasting blood glucose, HbA1c, insulin sensitivity, beta-cell function, cardiovascular events, congestive heart failure, hypoglycemia, weight gain, edema, gastrointestinal adverse effects, drug selection
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glyburide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Cholesterol, LDL, Male, Metformin, Middle Aged, Weight Gain, Proportional Hazards Models, Treatment Outcome, Thiazolidinediones, Waist-Hip Ratio, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.